Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kerry Lynn Reynolds, M.D.

Co-Author

This page shows the publications co-authored by Kerry Reynolds and Leyre Zubiri.
Connection Strength

6.384
  1. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.984
  2. Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist. 2021 08; 26(8):e1427-e1433.
    View in: PubMed
    Score: 0.964
  3. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21.
    View in: PubMed
    Score: 0.870
  4. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.870
  5. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.243
  6. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.243
  7. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Curr Treat Options Oncol. 2021 05 26; 22(6):53.
    View in: PubMed
    Score: 0.241
  8. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.239
  9. Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist. 2021 01; 26(1):49-55.
    View in: PubMed
    Score: 0.233
  10. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021 Oct 15; 158:99-110.
    View in: PubMed
    Score: 0.062
  11. Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction. Nephrol Dial Transplant. 2021 Aug 12.
    View in: PubMed
    Score: 0.061
  12. Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. Am J Kidney Dis. 2021 Jun 24.
    View in: PubMed
    Score: 0.061
  13. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv. 2021 Jan; 1(1):ltab014.
    View in: PubMed
    Score: 0.061
  14. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 06; 9(6).
    View in: PubMed
    Score: 0.060
  15. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist. 2021 08; 26(8):685-693.
    View in: PubMed
    Score: 0.060
  16. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901.
    View in: PubMed
    Score: 0.060
  17. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.059
  18. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.059
  19. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. J Vasc Interv Radiol. 2021 02; 32(2):187-195.
    View in: PubMed
    Score: 0.059
  20. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021 01; 9(1).
    View in: PubMed
    Score: 0.059
  21. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2020 Dec 29.
    View in: PubMed
    Score: 0.059
  22. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2020 12; 9(23):e018306.
    View in: PubMed
    Score: 0.058
  23. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124.
    View in: PubMed
    Score: 0.058
  24. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 Dec 15; 142(24):2299-2311.
    View in: PubMed
    Score: 0.058
  25. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.058
  26. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod Pathol. 2021 02; 34(2):426-437.
    View in: PubMed
    Score: 0.057
  27. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep. 2020 Oct; 5(10):1700-1705.
    View in: PubMed
    Score: 0.057
  28. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 06 16; 141(24):2031-2034.
    View in: PubMed
    Score: 0.057
  29. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918.
    View in: PubMed
    Score: 0.056
  30. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 12 06; 14(12):1692-1700.
    View in: PubMed
    Score: 0.054
  31. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219.
    View in: PubMed
    Score: 0.054
  32. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. J Am Acad Dermatol. 2020 03; 82(3):743-746.
    View in: PubMed
    Score: 0.053
  33. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019 Sep; 8(11):4986-4999.
    View in: PubMed
    Score: 0.053
  34. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019 05; 94(5):563-574.
    View in: PubMed
    Score: 0.052
  35. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol. 2019 03 01; 5(3):358-365.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.